The role of alternative splicing in lung cancer

Cancer Chemother Pharmacol. 2023 Aug;92(2):83-95. doi: 10.1007/s00280-023-04553-4. Epub 2023 Jun 19.

Abstract

Aberrant alternative splicing (AS) events are frequently observed in lung cancer, which can be attributed to aberrant gene AS, alterations in splicing regulatory factors, or changes in splicing regulatory mechanisms. Consequently, the dysregulation of alternative RNA splicing is the fundamental cause of lung cancer. In this review, we have summarized the pivotal role of AS in the development, progression, invasion, metastasis, angiogenesis, and drug resistance of lung cancer. Ultimately, this review emphasizes the potential of AS as biomarkers in lung cancer prognosis and diagnosis, and introduces some applications of AS isoform in the treatment of lung cancer. The comprehension of the AS may provide a glimmer of hope for the eradication of lung cancer.

Keywords: Alternative splicing; Diagnosis; Lung cancer; Prognosis; Treatment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alternative Splicing*
  • Biomarkers
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Prognosis
  • RNA Splicing Factors / genetics

Substances

  • RNA Splicing Factors
  • Biomarkers